Zika Virus Testing Market Size - By Test Type (Serological tests, Molecular Tests), By End User (Hospitals, Diagnostic Centers, Clinics, Public Health Laboratory) – Global Forecast to 2032

Zika Virus Testing Market Size

Zika Virus Testing Market size was valued at over USD 174 million in 2022 and is projected to reach more than USD 366 million by 2032.
 

Zika virus testing is a diagnostic procedure and technique used to detect the presence of the zika virus in individuals suspected of being infected. The zika virus is a mosquito-borne virus primarily transmitted by Aedes mosquitoes, although it can also be transmitted through sexual contact, blood transfusion, and from mother to foetus during pregnancy. Zika virus testing plays a crucial role in identifying infected individuals, implementing appropriate public health measures, monitoring the spread of the virus, and providing necessary medical care.
 

The zika virus testing market has garnered significant attention worldwide because of substantial awareness among healthcare professionals, governments, and the general public. Moreover, growing preference for point of care testing for zika virus owing to precised detection, effective patient management among low middle income countries will enhance market growth potential in near future.
 

The continuous advancements in molecular diagnostic technologies such as polymerase chain reaction and nucleic acid amplification techniques are estimated to further enhance the sensitivity, specificity, and speed of zika virus testing with more accurate and efficient diagnostics. Such innovations will contribute to accelerate market demand. Further, collaborative efforts among academic institutions, government agencies, and diagnostic companies are essential to drive innovation in zika virus testing.
 

COVID-19 Impact

The COVID-19 pandemic significantly impacted the world economy and positively influenced the zika virus testing market progression. Initially, the market suffered a setback due to the commencement of the lockdown and stringent regulations imposed by the authorities during the lockdown. In addition, the worldwide supply chain was disrupted, impacting the production and shipping of zika virus testing kits. However, the demand for multiplex testing increased during the COVID-19 pandemic. Since, these tests are used for multiple pathogens, including zika virus, has the potential to improve efficiency and reduce costs in testing efforts. Integrating zika virus testing into multiplex platforms enhanced surveillance and diagnostic capabilities.  
 

Moreover, the rise of telemedicine and remote consultations during the pandemic has provided an opportunity for healthcare professionals to offer guidance and support in zika virus testing remotely. Telehealth platforms enable experts to provide advice on test interpretation, patient management, and guidance in regions with limited access to specialized care.
 

Zika Virus Testing Market Trends

The zika virus infection has emerged as a significant global health concern due to its potential to cause severe birth defects and neurological complications. For instance, according to the World Health Organization (WHO), zika virus infection declared as endemic in Southeast Asia and Africa region. Thus, increasing prevalence of zika virus infection will increase demand for robust testing methods to detect and manage the disease effectively leading to surge in the demand for zika virus testing.
 

In addition, as zika virus infection becomes more prevalent, healthcare providers are integrating zika virus testing into routine care. This includes incorporating testing protocols into prenatal care, ensuring timely screening of pregnant women, and implementing surveillance programs to monitor the spread of the virus. Moreover, growing awareness campaigns to educate population, healthcare professionals and pregnant women about zika virus transmission, prevention, and the importance of testing will boost industry.
 

Zika Virus Testing Market Analysis

The zika virus testing market by test type is segmented into serological tests and molecular tests. The serological tests segment is further segmented into reverse transcription polymerase chain reaction (RT-PCR) and nucleic acid amplification testing (NAAT). The serological tests segment is categorized into enzyme-linked immune sorbent assay (ELISA) and plaque reduction and neutralization test (PRNT). The molecular tests segment is expected to witness CAGR of 7.8% by 2032..
 

For instance, real-time reverse transcription polymerase chain reaction (RT-PCR) is widely utilized for accurate and timely detection of zika virus RNA. Also, multiplex assays gaining popularity due to simultaneous detection of multiple pathogens including zika virus.
 

Moreover, point-of-care molecular diagnostic tests offer rapid results at the patient's bedside, while isothermal amplification methods provide simplified protocols and faster turnaround times. Thus, aforementioned advancements and availability of several testing techniques will propel segmental demand in the business. Further, automation and high-throughput systems streamline testing processes as well as ongoing research focuses on novel targets and biomarkers to enhance sensitivity and specificity are some of major factors contributing to segmental revenue gain.
 

The zika virus testing market by end user is categorized into hospitals, diagnostic centers, public health laboratory and others. Hospitals segment held largest revenue size accounting for over USD 70 million in 2022. The high revenue evolution is owing surge in the number of patients associated with zika virus infection. Growing availability and accessibility of novel technology into settings for detection of zika virus cases bolstering segmental expansion potential. Additionally, implementation of comprehensive surveillance systems to monitor the prevalence of the virus and identify potential outbreaks is predicted to accelerate segment growth in the market.
 

U.S. zika virus testing market accounted for over USD 40 million in 2022. Growing awareness and concern regarding the impact of zika virus on public health have been instrumental in driving the demand for zika virus testing. As, the U.S. being a popular travel destination, the high demand for zika virus testing owing to the need to screen individuals returning from regions with high zika virus prevalence.
 

In addition, favorable travel-related testing requirements and guidelines by the government and travel medicine providers will contribute to the development of the market. Further, sophisticated healthcare infrastructure, favorable reimbursement scenario, large presence of industry participants will boost the U.S. market in near future.
 

Zika Virus Testing Market Share

Some of the notable key industry players operating in the zika virus testing market include:

• Abbott Laboratories
• Altona Diagnostics GmbH
• ChemBio Diagnostics Inc
• ELITechGroup F
• Hoffmann-La Roche Ltd
• Genekam
• DiaSorin (Luminex Corporation)
• Novacyt Group
• Quest Diagnostics
• Siemens Healthcare GmbH
• LGC Limited (SeraCare Life Sciences)
• Co-Diagnostics Inc
• Mediven (Medical Innovation Ventures)
• Biocan Diagnostics Inc.
• Euroimmun
   

Zika Virus Testing Industry News:

• In July 2022, Mylab announced launch of PathoDetect Extended Monsoon Fever Panel, a multiplex assay RT-PCR test kit for several monsoon disorders such as zika, malaria, dengue among others. These compact kits provide accurate results within 2 hours and also offers mass testing. This launch offered competitive edge to the company in the significant market.
   
• In February 2022, Klenzaids launched BSL-3 enhanced laboratory in collaboration with Indian Council of Medical Research (ICMR) in Maharashtra. and collaboratively launched India's first in Maharashtra, India. This India’s first mobile laboratory is integrated with advanced equipments for detection of several infectious diseases such zika virus.
   

Zika virus testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Test Type (USD Million)

• Serological tests
• Reverse Transcription Polymerase Chain Reaction (RT-PCR)
• Nucleic Acid Amplification Testing (NAAT)

• Molecular tests
• Enzyme-Linked Immune Sorbent Assay (ELISA)
• Plaque Reduction and Neutralization Test (PRNT)

By End User (USD Million)

• Hospitals
• Diagnostic Centers
• Public Health Laboratory
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Belgium
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
  • Singapore
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Turkey